Table 2 Basal clinicopathologic characteristics of patients with breast cancer metastasis according to metastatic site
From: Site-specific metabolic phenotypes in metastatic breast cancer
Parameters | Total N = 162 (%) | Bone metastasis n = 47 (%) | Brain metastasis n = 39 (%) | Liver metastasis n = 24 (%) | Lung metastasis n = 52 (%) | p-value |
|---|---|---|---|---|---|---|
Age (yr, mean ± SD) | 52.0 ± 10.5 | 52.3 ± 10.0 | 53.5 ± 11.7 | 54.2 ± 10.8 | 49.7 ± 9.5 | 0.221 |
ER | Â | Â | Â | Â | Â | <0.001 |
  Negative | 69 (42.6) | 8 (17.0) | 26 (66.7) | 6 (25.0) | 29 (55.8) |  |
  Positive | 93 (57.4) | 39 (83.0) | 13 (33.3) | 18 (75.0) | 23 (44.2) |  |
PR | Â | Â | Â | Â | Â | <0.001 |
  Negative | 109 (67.3) | 23 (48.9) | 38 (97.4) | 12 (50.0) | 36 (69.2) |  |
  Positive | 53 (32.7) | 24 (51.1) | 1 (2.6) | 12 (50.0) | 16 (30.8) |  |
HER-2 | Â | Â | Â | Â | Â | 0.017 |
  Negative | 114 (70.4) | 38 (80.9) | 20 (51.3) | 19 (79.2) | 37 (71.2) |  |
  Positive | 48 (29.6) | 9 (19.1) | 19 (48.7) | 5 (20.8) | 15 (28.8) |  |
Molecular subtypes | Â | Â | Â | Â | Â | <0.001 |
  Luminal A | 67 (41.4) | 33 (70.2) | 4 (10.3) | 15 (62.5) | 15 (28.8) |  |
  Luminal B | 27 (16.7) | 7 (14.9) | 9 (23.1) | 3 (12.5) | 8 (15.4) |  |
  HER-2 | 30 (18.5) | 5 (10.6) | 12 (30.8) | 3 (12.5) | 10 (19.2) |  |
  TNBC | 38 (23.5) | 2 (4.3) | 14 (35.9) | 3 (12.5) | 19 (36.5) |  |
Time to metastasis (month, mean ± SD) | 30.3 ± 38.0 | 29.3 ± 29.2 | 32.7 ± 32.6 | 18.2 ± 16.8 | 35.1 ± 38.0 | 0.182 |
Patients death | 53 (32.7) | 23 (48.9) | 11 (28.2) | 7 (29.2) | 12 (23.1) | 0.040 |